Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 90 points (-0.6%) at 15,522 as of Tuesday, Aug. 6, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 580 issues advancing vs. 2,389 declining with 97 unchanged. The Health Services industry currently sits down 0.3% versus the S&P 500, which is down 0.6%. On the negative front, top decliners within the industry include Tenet Healthcare ( THC), down 4.4%, HCA Holdings ( HCA), down 2.3%, Boston Scientific ( BSX), down 1.1% and Aetna ( AET), down 0.7%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Mindray Medical International ( MR) is one of the companies pushing the Health Services industry lower today. As of noon trading, Mindray Medical International is down $0.85 (-2.0%) to $40.98 on heavy volume. Thus far, 722,058 shares of Mindray Medical International exchanged hands as compared to its average daily volume of 744,500 shares. The stock has ranged in price between $40.00-$42.20 after having opened the day at $41.39 as compared to the previous trading day's close of $41.83. Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International has a market cap of $4.8 billion and is part of the health care sector. Shares are up 27.9% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate Mindray Medical International a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Mindray Medical International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Mindray Medical International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.